American Journal of Clinical Dermatology

, Volume 18, Issue 2, pp 215–230 | Cite as

Facial Hyperpigmentation in Skin of Color: Special Considerations and Treatment

  • Neelam A. Vashi
  • Stephen A. Wirya
  • Meyene Inyang
  • Roopal V. Kundu
Therapy in Practice

Abstract

Differences in cutaneous diseases in people of color call for nuanced evaluation and management. One of the most common dermatological complaints from patients with skin of color is dyspigmentation, particularly hyperpigmentation. The challenge for clinicians is to establish correct diagnoses along with consistently successful treatments to meet the needs of the increasingly diverse population served. This review focuses on facial hyperpigmentation and outlines the most common skin disorders and treatment options.

Notes

Compliance with Ethical Standards

Funding

No funding was received for the preparation of this review.

Conflict of interest

Neelam A Vashi, Stephen A Wirya, Meyene Inyang, and Roopal V. Kundu have no conflicts of interest.

References

  1. 1.
    Larocca CA, Kundu RV, Vashi NA. Physiologic pigmentation: molecular mechanisms and clinical diversity. Pigm Int. 2014;1(2):44–51.CrossRefGoogle Scholar
  2. 2.
    Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007;80(5):387–94.PubMedGoogle Scholar
  3. 3.
    Kang SJ, Davis SA, Feldman SR, McMichael AJ. Dyschromia in skin of color. J Drugs Dermatol. 2014;13(4):401–6.PubMedGoogle Scholar
  4. 4.
    Pawaskar MD, Parikh P, Markowski T, McMichael AJ, Feldman SR, Balkrishnan R. Melasma and its impact on health-related quality of life in Hispanic women. J Dermatol Treat. 2007;18(1):5–9.CrossRefGoogle Scholar
  5. 5.
    Ikino JK, Nunes DH, Silva VP, Frode TS, Sens MM. Melasma and assessment of the quality of life in Brazilian women. An Bras Dermatol. 2015;90(2):196–200.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Khanna N, Rasool S. Facial melanoses: Indian perspective. Indian J Dermatol Venereol Leprol. 2011;77(5):552–63 (quiz 64).PubMedCrossRefGoogle Scholar
  7. 7.
    Cestari TF, Dantas LP, Boza JC. Acquired hyperpigmentations. An Bras Dermatol. 2014;89(1):11–25.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Handel AC, Miot LD, Miot HA. Melasma: a clinical and epidemiological review. An Bras Dermatol. 2014;89(5):771–82.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Rodrigues M, Pandya AG. Melasma: clinical diagnosis and management options. Australas J Dermatol. 2015;56(3):151–63.PubMedCrossRefGoogle Scholar
  10. 10.
    Achar A, Rathi SK. Melasma: a clinico-epidemiological study of 312 cases. Indian J Dermatol. 2011;56(4):380–2.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Ogita A, Funasaka Y, Ansai S, Kawana S, Saeki H. Melasma in a male patient due to estrogen therapy for prostate cancer. Ann Dermatol. 2015;27(6):763–4.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Stratigos AJ, Katsambas AD. Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients. Am J Clin Dermatol. 2004;5(3):161–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Kwon SH, Hwang YJ, Lee SK, Park KC. Heterogeneous pathology of melasma and its clinical implications. Int J Mol Sci. 2016;17(6):824–34.PubMedCentralCrossRefGoogle Scholar
  14. 14.
    Hernandez-Barrera R, Torres-Alvarez B, Castanedo-Cazares JP, Oros-Ovalle C, Moncada B. Solar elastosis and presence of mast cells as key features in the pathogenesis of melasma. Clin Exp Dermatol. 2008;33(3):305–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Torres-Alvarez B, Mesa-Garza IG, Castanedo-Cazares JP, Fuentes-Ahumada C, Oros-Ovalle C, Navarrete-Solis J, et al. Histochemical and immunohistochemical study in melasma: evidence of damage in the basal membrane. Am J Dermatopathol. 2011;33(3):291–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Duteil L, Cardot-Leccia N, Queille-Roussel C, Maubert Y, Harmelin Y, Boukari F, et al. Differences in visible light-induced pigmentation according to wavelengths: a clinical and histological study in comparison with UVB exposure. Pigment Cell Melanoma Res. 2014;27(5):822–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Boukari F, Jourdan E, Fontas E, Montaudie H, Castela E, Lacour JP, et al. Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial. J Am Acad Dermatol. 2015;72(1):189–90.e1.Google Scholar
  18. 18.
    Shankar K, Godse K, Aurangabadkar S, Lahiri K, Mysore V, Ganjoo A, et al. Evidence-based treatment for melasma: expert opinion and a review. Dermatol Ther. 2014;4(2):165–86.CrossRefGoogle Scholar
  19. 19.
    Molinar VE, Taylor SC, Pandya AG. What’s new in objective assessment and treatment of facial hyperpigmentation? Dermatol Clin. 2014;32(2):123–35.PubMedCrossRefGoogle Scholar
  20. 20.
    Lynde CB, Kraft JN, Lynde CW. Topical treatments for melasma and postinflammatory hyperpigmentation. Skin Ther Lett. 2006;11(9):1–6.Google Scholar
  21. 21.
    Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol. 2011;65(4):699–714 (quiz 5).PubMedCrossRefGoogle Scholar
  22. 22.
    Mazurek K, Pierzchala E. Comparison of efficacy of products containing azelaic acid in melasma treatment. J Cosmet Dermatol. 2016;15(3):269–82.PubMedCrossRefGoogle Scholar
  23. 23.
    Farshi S. Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma. J Cosmet Dermatol. 2011;10(4):282–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Sardana K, Chugh S, Garg V. Are Q-switched lasers for Nevus of Ota really effective in pigmented skin? Indian J Dermatol Venereol Leprol. 2012;78(2):187–9 (author reply 9–90).PubMedCrossRefGoogle Scholar
  25. 25.
    Hofbauer Parra CA, Careta MF, Valente NY, de Sanches Osorio NE, Torezan LA. Clinical and histopathologic assessment of facial melasma after low-fluence Q-switched neodymium-doped yttrium aluminium garnet laser. Dermatol Surg. 2016;42(4):507–12.PubMedCrossRefGoogle Scholar
  26. 26.
    Na JI, Choi SY, Yang SH, Choi HR, Kang HY, Park KC. Effect of tranexamic acid on melasma: a clinical trial with histological evaluation. J Eur Acad Dermatol Venereol. 2013;27(8):1035–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Tan AW, Sen P, Chua SH, Goh BK. Oral tranexamic acid lightens refractory melasma. Australas J Dermatol (Epub 13 May 2016).Google Scholar
  28. 28.
    Lee HC, Thng TG, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis. J Am Acad Dermatol. 2016;75(2):385–92.PubMedCrossRefGoogle Scholar
  29. 29.
    Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20–31.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, Finkel LJ, Hamilton TA, Ellis CN, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328(20):1438–43.PubMedCrossRefGoogle Scholar
  31. 31.
    Lowe NJ, Rizk D, Grimes P, Billips M, Pincus S. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther. 1998;20(5):945–59.PubMedCrossRefGoogle Scholar
  32. 32.
    Kakita LS, Lowe NJ. Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: a clinical comparison with hydroquinone. Clin Ther. 1998;20(5):960–70.PubMedCrossRefGoogle Scholar
  33. 33.
    Alexis AF, Blackcloud P. Natural ingredients for darker skin types: growing options for hyperpigmentation. J Drugs Dermatol. 2013;12(9 Suppl):s123–7.PubMedGoogle Scholar
  34. 34.
    Fleischer AB Jr, Schwartzel EH, Colby SI, Altman DJ. The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol. 2000;42(3):459–67.PubMedCrossRefGoogle Scholar
  35. 35.
    Jarratt M. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis. 2004;74(5):319–22.PubMedGoogle Scholar
  36. 36.
    Lee do H, Oh IY, Koo KT, Suk JM, Jung SW, Park JO, et al. Reduction in facial hyperpigmentation after treatment with a combination of topical niacinamide and tranexamic acid: a randomized, double-blind, vehicle-controlled trial. Skin Res Technol. 2014;20(2):208–12.PubMedCrossRefGoogle Scholar
  37. 37.
    Vashi NA, Kundu RV. Approach to the patient with hyperpigmentation disorders. 2015. http://www.uptodate.com/contents/approach-to-the-patient-with-hyperpigmentation-disorders#H804857. Accessed 6 Sept 2016.
  38. 38.
    Sonthalia S, Sarkar R. Maturational hyperpigmentation. In: Koushik L, Chaterjee M, Sarkar R, editors. Pigmentary disorders: a comprehensive compendium. 1st ed. New Delhi: Jaypee Brothers Medical; 2014.Google Scholar
  39. 39.
    Cunliffe T. Hyperpigmentation—of the face and neck. 2013. http://www.pcds.org.uk/clinical-guidance/melasma-syn.-chloasma-and-other-causes-of-facial-hyperpigmentation. Accessed 6 Sept 2016.
  40. 40.
    Besra L, Jaisankar TJ, Thappa DM, Malathi M, Kumari R. Spectrum of periorbital dermatoses in South Indian population. Indian J Dermatol Venereol Leprol. 2013;79(3):399–407.PubMedCrossRefGoogle Scholar
  41. 41.
    Sahni K, Kassir M. Dermafrac: an innovative new treatment for periorbital melanosis in a dark-skinned male patient. J Cutan Aesthet Surg. 2013;6(3):158–60.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Malakar S, Lahiri K, Banerjee U, Mondal S, Sarangi S. Periorbital melanosis is an extension of pigmentary demarcation line-F on face. Indian J Dermatol Venereol Leprol. 2007;73(5):323–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Roberts WE. Periorbital hyperpigmentation: review of etiology, medical evaluation, and aesthetic treatment. J Drugs Dermatol. 2014;13(4):472–82.PubMedGoogle Scholar
  44. 44.
    Alsaad SM, Mikhail M. Periocular hyperpigmentation: a review of etiology and current treatment options. J Drugs Dermatol. 2013;12(2):154–7.PubMedGoogle Scholar
  45. 45.
    Sarkar R, Ranjan R, Garg S, Garg VK, Sonthalia S, Bansal S. Periorbital hyperpigmentation: a comprehensive review. J Clin Aesthet Dermatol. 2016;9(1):49–55.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol. 2001;2(4):213–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Merola JF, Meehan S, Walters RF, Brown L. Exogenous ochronosis. Dermatol Online J. 2008;14(10):6.PubMedGoogle Scholar
  48. 48.
    Simmons BJ, Griffith RD, Bray FN, Falto-Aizpurua LA, Nouri K. Exogenous ochronosis: a comprehensive review of the diagnosis, epidemiology, causes, and treatments. Am J Clin Dermatol. 2015;16(3):205–12.PubMedCrossRefGoogle Scholar
  49. 49.
    Liu WC, Tey HL, Lee JS, Goh BK. Exogenous ochronosis in a Chinese patient: use of dermoscopy aids early diagnosis and selection of biopsy site. Singapore Med J. 2014;55(1):e1–3.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Chowdary S, Mahalingam M, Vashi NA. Reading between the layers: early histopathological findings in exogenous ochronosis. Am J Dermatopathol. 2014;36(12):989–91.PubMedCrossRefGoogle Scholar
  51. 51.
    Chaptini C, Huilgol SC. Erbium-doped yttrium aluminium garnet ablative laser treatment for endogenous ochronosis. Australas J Dermatol. 2015;56(3):212–4.PubMedCrossRefGoogle Scholar
  52. 52.
    Tan SK. Exogenous ochronosis—successful outcome after treatment with Q-switched Nd:YAG laser. J Cosmet Laser Ther. 2013;15(5):274–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Kramer KE, Lopez A, Stefanato CM, Phillips TJ. Exogenous ochronosis. J Am Acad Dermatol. 2000;42(5 Pt 2):869–71.PubMedCrossRefGoogle Scholar
  54. 54.
    Bellew SG, Alster TS. Treatment of exogenous ochronosis with a Q-switched alexandrite (755 nm) laser. Dermatol Surg. 2004;30(4 Pt 1):555–8.PubMedGoogle Scholar
  55. 55.
    Kanechorn-Na-Ayuthaya P, Niumphradit N, Aunhachoke K, Nakakes A, Sittiwangkul R, Srisuttiyakorn C. Effect of combination of 1064 nm Q-switched Nd:YAG and fractional carbon dioxide lasers for treating exogenous ochronosis. J Cosmet Laser Ther. 2013;15(1):42–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Schwartz RA. Acanthosis nigricans. J Am Acad Dermatol. 1994;31(1):1–19 (quiz 20–2).PubMedCrossRefGoogle Scholar
  57. 57.
    Phiske MM. An approach to acanthosis nigricans. Indian Dermatol Online J. 2014;5(3):239–49.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Sinha S, Schwartz RA. Juvenile acanthosis nigricans. J Am Acad Dermatol. 2007;57(3):502–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Kutlubay Z, Engin B, Bairamov O, Tuzun Y. Acanthosis nigricans: a fold (intertriginous) dermatosis. Clin Dermatol. 2015;33(4):466–70.PubMedCrossRefGoogle Scholar
  60. 60.
    Park YJ, Kang HY, Lee ES, Kim YC. Differentiating confluent and reticulated papillomatosis from acanthosis nigricans. J Cutan Pathol (Epub 12 Aug 2015).Google Scholar
  61. 61.
    Sriboonnark L, Arora H, Falto-Aizpurua L, Choudhary S, Connelly EA. Costello syndrome with severe nodulocystic acne: unexpected significant improvement of acanthosis nigricans after oral isotretinoin treatment. Case Rep Pediatr. 2015;2015:934865.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Rosenbach A, Ram R. Treatment of Acanthosis nigricans of the axillae using a long-pulsed (5-msec) alexandrite laser. Dermatol Surg. 2004;30(8):1158–60.PubMedGoogle Scholar
  63. 63.
    Gregoriou S, Anyfandakis V, Kontoleon P, Christofidou E, Rigopoulos D, Kontochristopoulos G. Acanthosis nigricans associated with primary hypogonadism: successful treatment with topical calcipotriol. J Dermatolog Treat. 2008;19(6):373–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Niang SO, Kane A, Diallo M, Choutah F, Dieng MT, Ndiaye B. Dermatosis papulosa nigra in Dakar, Senegal. Int J Dermatol. 2007;46(Suppl 1):45–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Vashi NA, Kundu RV. Facial hyperpigmentation: causes and treatment. Br J Dermatol. 2013;169(Suppl 3):41–56.PubMedCrossRefGoogle Scholar
  66. 66.
    Lupo MP. Dermatosis papulosis nigra: treatment options. J Drugs Dermatol. 2007;6(1):29–30.PubMedGoogle Scholar
  67. 67.
    Hafner C, Landthaler M, Mentzel T, Vogt T. FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra. Br J Dermatol. 2010;162(3):508–12.PubMedCrossRefGoogle Scholar
  68. 68.
    Babapour R, Leach J, Levy H. Dermatosis papulosa nigra in a young child. Pediatr Dermatol. 1993;10(4):356–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Veraitch O, Rickaby W, Robson A, Higgins E, Mellerio JE. Early-onset dermatosis papulosa nigra. Br J Dermatol. 2016;174(5):1148–50.PubMedCrossRefGoogle Scholar
  70. 70.
    Garcia MS, Azari R, Eisen DB. Treatment of dermatosis papulosa nigra in 10 patients: a comparison trial of electrodesiccation, pulsed dye laser, and curettage. Dermatol Surg. 2010;36(12):1968–72.PubMedCrossRefGoogle Scholar
  71. 71.
    Kundu RV, Joshi SS, Suh KY, Boone SL, Huggins RH, Alam M, et al. Comparison of electrodesiccation and potassium-titanyl-phosphate laser for treatment of dermatosis papulosa nigra. Dermatol Surg. 2009;35(7):1079–83.PubMedCrossRefGoogle Scholar
  72. 72.
    Ali FR, Bakkour W, Ferguson JE, Madan V. Carbon dioxide laser ablation of dermatosis papulosa nigra: high satisfaction and few complications in patients with pigmented skin. Lasers Med Sci. 2016;31(3):593–5.PubMedCrossRefGoogle Scholar
  73. 73.
    Bruscino N, Conti R, Campolmi P, Bonan P, Cannarozzo G, Lazzeri L, et al. Dermatosis Papulosa Nigra and 10,600-nm CO2 laser, a good choice. J Cosmet Laser Ther. 2014;16(3):114–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Katz TM, Goldberg LH, Friedman PM. Dermatosis papulosa nigra treatment with fractional photothermolysis. Dermatol Surg. 2009;35(11):1840–3.PubMedCrossRefGoogle Scholar
  75. 75.
    Hori Y, Kawashima M, Oohara K, Kukita A. Acquired, bilateral nevus of Ota-like macules. J Am Acad Dermatol. 1984;10(6):961–4.PubMedCrossRefGoogle Scholar
  76. 76.
    Park JM, Tsao H, Tsao S. Acquired bilateral nevus of Ota-like macules (Hori nevus): etiologic and therapeutic considerations. J Am Acad Dermatol. 2009;61(1):88–93.PubMedCrossRefGoogle Scholar
  77. 77.
    Ee HL, Wong HC, Goh CL, Ang P. Characteristics of Hori naevus: a prospective analysis. Br J Dermatol. 2006;154(1):50–3.PubMedCrossRefGoogle Scholar
  78. 78.
    Murakami F, Soma Y, Mizoguchi M. Acquired symmetrical dermal melanocytosis (naevus of Hori) developing after aggravated atopic dermatitis. Br J Dermatol. 2005;152(5):903–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Lee B, Kim YC, Kang WH, Lee ES. Comparison of characteristics of acquired bilateral nevus of Ota-like macules and nevus of Ota according to therapeutic outcome. J Korean Med Sci. 2004;19(4):554–9.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Lam AY, Wong DS, Lam LK, Ho WS, Chan HH. A retrospective study on the efficacy and complications of Q-switched alexandrite laser in the treatment of acquired bilateral nevus of Ota-like macules. Dermatol Surg. 2001;27(11):937–41 (discussion 41–2).PubMedGoogle Scholar
  81. 81.
    Kunachak S, Kunachakr S, Sirikulchayanonta V, Leelaudomniti P. Dermabrasion is an effective treatment for acquired bilateral nevus of Ota-like macules. Dermatol Surg. 1996;22(6):559–62.PubMedCrossRefGoogle Scholar
  82. 82.
    Lee WJ, Han SS, Chang SE, Lee MW, Choi JH, Moon KC, et al. Q-Switched Nd:YAG Laser therapy of acquired bilateral mevus of ota-like macules. Ann Dermatol. 2009;21(3):255–60.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Cho SB, Park SJ, Kim MJ, Bu TS. Treatment of acquired bilateral nevus of Ota-like macules (Hori’s nevus) using 1064-nm Q-switched Nd:YAG laser with low fluence. Int J Dermatol. 2009;48(12):1308–12.PubMedCrossRefGoogle Scholar
  84. 84.
    Manuskiatti W, Sivayathorn A, Leelaudomlipi P, Fitzpatrick RE. Treatment of acquired bilateral nevus of Ota-like macules (Hori’s nevus) using a combination of scanned carbon dioxide laser followed by Q-switched ruby laser. J Am Acad Dermatol. 2003;48(4):584–91.PubMedCrossRefGoogle Scholar
  85. 85.
    Tian BW. Novel treatment of Hori’s nevus: a combination of fractional nonablative 2,940-nm Er:YAG and low-fluence 1,064-nm Q-switched Nd:YAG laser. J Cutan Aesthet Surg. 2015;8(4):227–9.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Ee HL, Goh CL, Khoo LS, Chan ES, Ang P. Treatment of acquired bilateral nevus of ota-like macules (Hori’s nevus) with a combination of the 532 nm Q-Switched Nd:YAG laser followed by the 1,064 nm Q-switched Nd:YAG is more effective: prospective study. Dermatol Surg. 2006;32(1):34–40.PubMedCrossRefGoogle Scholar
  87. 87.
    Yamaguchi K, Watanabe C, Kawaguchi A, Sato T, Naka I, Shindo M, et al. Association of melanocortin 1 receptor gene (MC1R) polymorphisms with skin reflectance and freckles in Japanese. J Hum Genet. 2012;57(11):700–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Ezzedine K, Mauger E, Latreille J, Jdid R, Malvy D, Gruber F, et al. Freckles and solar lentigines have different risk factors in Caucasian women. J Eur Acad Dermatol Venereol. 2013;27(3):e345–56.PubMedCrossRefGoogle Scholar
  89. 89.
    Rhodes AR, Albert LS, Barnhill RL, Weinstock MA. Sun-induced freckles in children and young adults. A correlation of clinical and histopathologic features. Cancer. 1991;67(7):1990–2001.PubMedCrossRefGoogle Scholar
  90. 90.
    Bastiaens M, ter Huurne J, Gruis N, Bergman W, Westendorp R, Vermeer BJ, et al. The melanocortin-1-receptor gene is the major freckle gene. Hum Mol Genet. 2001;10(16):1701–8.PubMedCrossRefGoogle Scholar
  91. 91.
    Gold MH, Gallagher C. An evaluation of the benefits of a topical treatment in the improvement of photodamaged hands with age spots, freckles, and/or discolorations. J Drugs Dermatol. 2013;12(12):1468–72.PubMedGoogle Scholar
  92. 92.
    Mradula PR, Sacchidanand S. A split-face comparative study of 70% trichloroacetic acid and 80% phenol spot peel in the treatment of freckles. J Cutan Aesthet Surg. 2012;5(4):261–5.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Huang YL, Liao YL, Lee SH, Hong HS. Intense pulsed light for the treatment of facial freckles in Asian skin. Dermatol Surg. 2002;28(11):1007–12 (discussion 12).PubMedGoogle Scholar
  94. 94.
    Ho SG, Yeung CK, Chan NP, Shek SY, Chan HH. A comparison of Q-switched and long-pulsed alexandrite laser for the treatment of freckles and lentigines in oriental patients. Lasers Surg Med. 2011;43(2):108–13.PubMedCrossRefGoogle Scholar
  95. 95.
    El Zawahry B, Zaki N, Hafez V, Abdel Hay R, Fahim A. Efficacy and safety of fractional carbon dioxide laser for treatment of unwanted facial freckles in phototypes II-IV: a pilot study. Lasers Med Sci. 2014;29(6):1937–42.PubMedCrossRefGoogle Scholar
  96. 96.
    Andersen WK, Labadie RR, Bhawan J. Histopathology of solar lentigines of the face: a quantitative study. J Am Acad Dermatol. 1997;36(3 Pt 1):444–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Ortonne JP, Pandya AG, Lui H, Hexsel D. Treatment of solar lentigines. J Am Acad Dermatol. 2006;54(5 Suppl 2):S262–71.PubMedCrossRefGoogle Scholar
  98. 98.
    Dlova NC. Frontal fibrosing alopecia and lichen planus pigmentosus: is there a link? Br J Dermatol. 2013;168(2):439–42.PubMedCrossRefGoogle Scholar
  99. 99.
    Rao R, Sarda A, Khanna R, Balachandran C. Coexistence of frontal fibrosing alopecia with lichen planus pigmentosus. Int J Dermatol. 2014;53(5):622–4.PubMedCrossRefGoogle Scholar
  100. 100.
    Berliner JG, McCalmont TH, Price VH, Berger TG. Frontal fibrosing alopecia and lichen planus pigmentosus. J Am Acad Dermatol. 2014;71(1):e26–7.PubMedCrossRefGoogle Scholar
  101. 101.
    Patel AB, Kubba R, Kubba A. Clinicopathological correlation of acquired hyperpigmentary disorders. Indian J Dermatol Venereol Leprol. 2013;79(3):367–75.PubMedCrossRefGoogle Scholar
  102. 102.
    Rieder E, Kaplan J, Kamino H, Sanchez M, Pomeranz MK. Lichen planus pigmentosus. Dermatol Online J. 2013;19(12):20713.PubMedGoogle Scholar
  103. 103.
    Chen S, Sun W, Zhou G, Chen S, Lu X. Lichen planus pigmentosus-inversus: report of three Chinese cases and review of the published work. J Dermatol. 2015;42(1):77–80.PubMedCrossRefGoogle Scholar
  104. 104.
    Nijhawan RI, Borkin MS, Wilentz SW. Lichen planus pigmentosus-inversus involving the post-auricular sulci. Dermatol Online J. 2013;19(6):18571.PubMedGoogle Scholar
  105. 105.
    Al-Mutairi N, El-Khalawany M. Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study. J Eur Acad Dermatol Venereol. 2010;24(5):535–40.PubMedCrossRefGoogle Scholar
  106. 106.
    Verma P, Pandhi D. Topical tacrolimus and oral dapsone combination regimen in lichen Planus pigmentosus. Skinmed. 2015;13(5):351–4.PubMedGoogle Scholar
  107. 107.
    Kim JE, Won CH, Chang S, Lee MW, Choi JH, Moon KC. Linear lichen planus pigmentosus of the forehead treated by neodymium:yttrium-aluminum-garnet laser and topical tacrolimus. J Dermatol. 2012;39(2):189–91.PubMedCrossRefGoogle Scholar
  108. 108.
    Han XD, Goh CL. A case of lichen planus pigmentosus that was recalcitrant to topical treatment responding to pigment laser treatment. Dermatol Ther. 2014;27(5):264–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Muthu SK, Narang T, Saikia UN, Kanwar AJ, Parsad D, Dogra S. Low-dose oral isotretinoin therapy in lichen planus pigmentosus: an open-label non-randomized prospective pilot study. Int J Dermatol. 2016;55(9):1048–54.PubMedCrossRefGoogle Scholar
  110. 110.
    Vega ME, Waxtein L, Arenas R, Hojyo T, Dominguez-Soto L. Ashy dermatosis and lichen planus pigmentosus: a clinicopathologic study of 31 cases. Int J Dermatol. 1992;31(2):90–4.PubMedCrossRefGoogle Scholar
  111. 111.
    Correa MC, Memije EV, Vargas-Alarcon G, Guzman RA, Rosetti F, Acuna-Alonzo V, et al. HLA-DR association with the genetic susceptibility to develop ashy dermatosis in Mexican Mestizo patients. J Am Acad Dermatol. 2007;56(4):617–20.PubMedCrossRefGoogle Scholar
  112. 112.
    Torrelo A, Zaballos P, Colmenero I, Mediero IG, de Prada I, Zambrano A. Erythema dyschromicum perstans in children: a report of 14 cases. J Eur Acad Dermatol Venereol. 2005;19(4):422–6.PubMedCrossRefGoogle Scholar
  113. 113.
    Srivastava N, Solanki LS, Chand S, Garbyal RS, Singh S. Ashy dermatosis-like pigmentation due to ethambutol. Indian J Dermatol Venereol Leprol. 2008;74(3):281–2.PubMedCrossRefGoogle Scholar
  114. 114.
    Tlougan BE, Gonzalez ME, Mandal RV, Kundu RV, Skopicki D. Erythema dyschromicum perstans. Dermatol Online J. 2010;16(11):17.PubMedGoogle Scholar
  115. 115.
    Zaynoun S, Rubeiz N, Kibbi AG. Ashy dermatoses–a critical review of the literature and a proposed simplified clinical classification. Int J Dermatol. 2008;47(6):542–4.PubMedCrossRefGoogle Scholar
  116. 116.
    Silverberg NB, Herz J, Wagner A, Paller AS. Erythema dyschromicum perstans in prepubertal children. Pediatr Dermatol. 2003;20(5):398–403.PubMedCrossRefGoogle Scholar
  117. 117.
    Mahajan VK, Chauhan PS, Mehta KS, Sharma AL. Erythema Dyschromicum Perstans: response to Topical Tacrolimus. Indian J Dermatol. 2015;60(5):525.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Baranda L, Torres-Alvarez B, Cortes-Franco R, Moncada B, Portales-Perez DP, Gonzalez-Amaro R. Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy. Arch Dermatol. 1997;133(3):325–9.PubMedCrossRefGoogle Scholar
  119. 119.
    Piquero-Martin J, Perez-Alfonzo R, Abrusci V, Briceno L, Gross A, Mosca W, et al. Clinical trial with clofazimine for treating erythema dyschromicum perstans. Evaluation of cell-mediated immunity. Int J Dermatol. 1989;28(3):198–200.PubMedCrossRefGoogle Scholar
  120. 120.
    Fabbrocini G, Cacciapuoti S, Izzo R, Mascolo M, Staibano S, Monfrecola G. Efficacy of narrowband UVB phototherapy in erythema dyschromicum perstans treatment: case reports. Acta Dermatovenerol Croat. 2015;23(1):63–5.PubMedGoogle Scholar
  121. 121.
    Chandran V, Kumarasinghe SP. Macular pigmentation of uncertain aetiology revisited: two case reports and a proposed algorithm for clinical classification. Australas J Dermatol (Epub 1 Feb 2016).Google Scholar
  122. 122.
    Dedhia A, Someshwar S, Jerajani HR. Idiopathic eruptive macular pigmentation: what is it actually? Int J Dermatol. 2015;54(12):1462–5.PubMedCrossRefGoogle Scholar
  123. 123.
    Verma S, Thakur BK. Idiopathic eruptive macular pigmentation with papillomatosis. Indian Dermatol Online J. 2011;2(2):101–3.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Riyaz N, Riyaz A, Abdul Latheef EN, Anitha PM, Aravindan KP, Nair AS, et al. Cutaneous manifestations of chikungunya during a recent epidemic in Calicut, north Kerala, south India. Indian J Dermatol Venereol Leprol. 2010;76(6):671–6.PubMedCrossRefGoogle Scholar
  125. 125.
    Kandhari R, Khunger N, Singh A. Flagellate pigmentation and exacerbation of melasma following chikungunya fever: a less frequently reported finding. Indian J Dermatol Venereol Leprol. 2012;78(6):774.PubMedCrossRefGoogle Scholar
  126. 126.
    Khandelwal K, Aara N, Ghiya BC, Bumb RA, Satoskar AR. Centro-facial pigmentation in asymptomatic congenital chikungunya viral infection. J Paediatr Child Health. 2012;48(6):542–3.PubMedCrossRefGoogle Scholar
  127. 127.
    Perez-Bernal A, Munoz-Perez MA, Camacho F. Management of facial hyperpigmentation. Am J Cli Dermatol. 2000;1(5):261–8.CrossRefGoogle Scholar
  128. 128.
    Luna PC, Abad ME, Gonzalez VM, Vigovich F, Casas JG, Larralde M. Erythrosis pigmentosa peribuccalis in an adolescent: dermoscopic description and management. Pediatric Dermatol. 2016;33(2):e65–8.CrossRefGoogle Scholar
  129. 129.
    Bovenschen HJ, Seyger MM. Erythrosis pigmentosa mediofacialis: familial occurrence. Acta Dermatovenereol. 2009;89(2):210–1.Google Scholar
  130. 130.
    Al Hawsawi K, Aljuhani O, Niaz G, Fallatah H, Alhawsawi A. Erythromelanosis follicularis faciei: a case report and review of the literature. Case Rep Dermatol. 2015;7(3):335–9.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Hawayek LH, Rubeiz N. Poikiloderma of civatte workup. Medscape; 2014.Google Scholar
  132. 132.
    Katoulis AC, Stavrianeas NG, Georgala S, Bozi E, Kalogeromitros D, Koumantaki E, et al. Poikiloderma of Civatte: a clinical and epidemiological study. J Eur Acad Dermatol Venereol. 2005;19(4):444–8.PubMedCrossRefGoogle Scholar
  133. 133.
    Katoulis AC, Stavrianeas NG, Georgala S, Katsarou-Katsari A, Koumantaki-Mathioudaki E, Antoniou C, et al. Familial cases of poikiloderma of Civatte: genetic implications in its pathogenesis? Clin Exp Dermatol. 1999;24(5):385–7.PubMedCrossRefGoogle Scholar
  134. 134.
    Salman SM, Kibbi AG, Zaynoun S. Actinic lichen planus. A clinicopathologic study of 16 patients. J Am Acad Dermatol. 1989;20(2 Pt 1):226–31.Google Scholar
  135. 135.
    Salman SM, Khallouf R, Zaynoun S. Actinic lichen planus mimicking melasma. A clinical and histopathologic study of three cases. J Am Acad Dermatol. 1988;18(2 Pt 1):275–8.Google Scholar
  136. 136.
    Wang L, Xu AE. Four views of Riehl’s melanosis: clinical appearance, dermoscopy, confocal microscopy and histopathology. J Eur Acad Dermatol Venereol. 2014;28(9):1199–206.PubMedCrossRefGoogle Scholar
  137. 137.
    Mohan RP, Verma S, Singh AK, Singh U. ‘Nevi of Ota: the unusual birthmarks’: a case review. BMJ Case Rep. 2013;2013:PII:BCR2013008648.Google Scholar
  138. 138.
    Goyal S, Uwaydat SH, Phillips PH, Schaefer GB. Bilateral familial nevus of Ota. J AAPOS. 2014;18(6):609–10.PubMedCrossRefGoogle Scholar
  139. 139.
    Trese MT, Pettit TH, Foos RY, Hofbauer J. Familial Nevus of Ota. Ann Ophthalmol. 1981;13(7):855–7.PubMedGoogle Scholar
  140. 140.
    Lindsey SF, Sanchez MI, Elgart GW, Milikowski C, Civantos FJ, Goldberg J, et al. Malignant melanoma from a nevus of Ota in a pediatric patient with fatal outcome. J Am Acad Dermatol. 2013;69(4):e195–7.PubMedCrossRefGoogle Scholar
  141. 141.
    Samadian M, Nejad AM, Bakhtevari MH, Sabeti S, Sharifi G, Jabbari R, et al. Primary meningeal melanocytoma in the left temporal lobe associated with nevus ota: a case report and review of the literature. World Neurosurg. 2015;84(2):567–73.PubMedCrossRefGoogle Scholar
  142. 142.
    Goldman-Levy G, Rigau V, Blechet C, Bens G, Muckensturm B, Delage M, et al. Primary melanoma of the leptomeninges with BAP1 expression-loss in the setting of a nevus of ota: a clinical, morphological and genetic study of 2 cases. Brain Pathol. 2016;26(4):547–50.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Neelam A. Vashi
    • 1
  • Stephen A. Wirya
    • 1
  • Meyene Inyang
    • 2
  • Roopal V. Kundu
    • 3
  1. 1.Department of DermatologyBoston University School of MedicineBostonUSA
  2. 2.Howard University College of MedicineWashingtonUSA
  3. 3.Department of DermatologyNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations